X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OP-3136 is an orally bioavailable, potent KAT6A/B-selective inhibitor. It is discovered and selected as a lead candidate for the treatment of breast cancer.
Lead Product(s): OP-3136
Therapeutic Area: Oncology Product Name: OP-3136
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Olema Oncology
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of CA-4948 (emavusertib).
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Product Name: CA-4948
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Curis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
Under the terms of the collaboration agreement, Aurigene will lead drug discovery and pre-clinical development efforts, and EQRx will assume responsibility for clinical development, manufacturing, regulatory and commercialization efforts.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: EQRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 05, 2022
Details:
Under the terms of the agreement, Olema and Aurigene will jointly direct preclinical work and, if successful, Olema will lead clinical development as well as regulatory and commercial activities.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Olema Oncology
Deal Size: $438.0 million Upfront Cash: $8.0 million
Deal Type: Collaboration June 09, 2022
Details:
In preclinical development, XL114 also demonstrated a high degree of selectivity against a broad safety pharmacology panel of enzymes and receptors.
Lead Product(s): XL114
Therapeutic Area: Oncology Product Name: AUR104
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: $22.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 14, 2021
Details:
Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.
Lead Product(s): XL102
Therapeutic Area: Oncology Product Name: XL102
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Exelixis
Deal Size: $29.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement December 07, 2020
Details:
Detailed characterization of an oral inhibitor of CDK7 demonstrates potent activity against multiple hematologic and solid tumor cell lines, as monotherapy and in combination with chemotherapies.
Lead Product(s): AUR102
Therapeutic Area: Oncology Product Name: AUR102
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Exelixis
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2020
Details:
The initiation of this phase II study represents a significant milestone for Aurigene, as it marks the first program which Aurigene has led from the bench side to the clinic all by itself.
Lead Product(s): AUR101
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020
Details:
Aurigene to fund and conduct a Phase 2b/3 randomized study of CA-170 in patients with non-squamous non-small cell lung cancer. Curis retains U.S., E.U., and rest of world rights to CA-170.
Lead Product(s): 3-Aminopyrrolidine dihydrochloride
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Curis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
